Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 6/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.61 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.59 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925494 | 0.92 | ADAMTS5 (0.69) | AKR1B1PTPN1ADAMTS5 | |
| SCHEMBL2931055 | 0.90 | ADAMTS5 (0.70) | AKR1B1PTPN1ADAMTS5 | |
| SCHEMBL2933475 | 0.87 | AKR1B1 (0.60) | AKR1B1PTPN1ADAMTS5 | |
| SCHEMBL2932473 | 0.86 | ADAMTS5 (0.67) | AKR1B1PTPN1ADAMTS5 | |
| SCHEMBL2932935 | 0.83 | PTPN22 (0.53) | AKR1B1PTPN1 | |
| SCHEMBL21326681 | 0.83 | ADAMTS5 (0.82) | AKR1B1PTPN1ADAMTS5 | |
| SCHEMBL2929627 | 0.82 | MEN1 (0.51) | AKR1B1PTPN1ADAMTS5 | |
| SCHEMBL7142541 | 0.82 | ADAMTS5 (0.80) | AKR1B1PTPN1PTPN2ADAMTS5 | |
| SCHEMBL7142543 | 0.82 | ADAMTS5 (0.80) | AKR1B1PTPN1PTPN2ADAMTS5 | |
| SCHEMBL5219686 | 0.81 | ADAMTS5 (0.84) | AKR1B1PTPN1ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313731-B1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | UCB SA (BE) | 2010-09-29 | — | — | EP | claimed |
| US-6740670-B2 | SUCH AS 5-(((3-(N-METHYL-N-PHENYLAMINO)CARBONYL-4-(PHENYL-METHOXY)) -PHENYL)METHYLENE)-4-OXO-2-THIOXO-3-THIAZOLIDINE-ACETIC ACID | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2004-05-25 | — | — | US | claimed |
| US-20030216453-A1 | Thiazolidine derivatives and its use as antifungal agent | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-11-20 | — | — | US | claimed |
| EP-1313731-A1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | Oxford GlycoSciences (UK) Limited (GB) | 2003-05-28 | — | — | EP | claimed |
| WO-2002022612-A1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 2002-03-21 | — | — | WO | claimed |
| EP-1313731-B1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | UCB SA (BE) | 2010-09-29 | — | — | EP | disclosed |
| US-6740670-B2 | SUCH AS 5-(((3-(N-METHYL-N-PHENYLAMINO)CARBONYL-4-(PHENYL-METHOXY)) -PHENYL)METHYLENE)-4-OXO-2-THIOXO-3-THIAZOLIDINE-ACETIC ACID | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2004-05-25 | — | — | US | disclosed |
| US-20030216453-A1 | Thiazolidine derivatives and its use as antifungal agent | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1313731-A1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | Oxford GlycoSciences (UK) Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002022612-A1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216453-A1 | Thiazolidine derivatives and its use as antifungal agent | CYP3A7, TAS2R7, OXSR1 | AKR1B1 489/4885PTPN1 654/4885PTPN2 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.